|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 20.38 USD | -0.49% |
|
+6.26% | +61.75% |
| 09-23 | Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says | MT |
| 09-23 | Oppenheimer Initiates Amneal Pharmaceuticals at Outperform With $27 Price Target | MT |
| Market Cap | 7.1B 6.34B 5.86B 5.31B 9.93B 674B 10.09B 70.47B 27.9B 353B 26.64B 26.07B 1,113B | P/E 2026 * |
41.9x | P/E 2027 * | 31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.53B 8.51B 7.86B 7.13B 13.33B 905B 13.55B 94.62B 37.46B 474B 35.77B 35.01B 1,495B | EV / Sales 2026 * |
3.02x | EV / Sales 2027 * | 2.67x |
| Free-Float |
44.36% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| AMRX | Delayed | |
CBOE
| AMRX | Real-time | |
|
Börse Stuttgart
| 2DT | Delayed | |
|
Deutsche Boerse AG
| 2DT | Delayed | |
|
Tradegate
| 2DT | Real-time | |
|
Boerse Muenchen
| 2DT | Real-time |
Last Transcript: Amneal Pharmaceuticals, Inc.
| 1 day | -0.49% | ||
| 1 week | +6.26% | ||
| Current month | +1.19% | ||
| 1 month | +2.90% | ||
| 3 months | +13.73% | ||
| 6 months | +62.78% | ||
| Current year | +61.75% |
| 1 week | 18.95 |  | 20.58 |
| 1 month | 18.78 | | 20.78 |
| Current year | 11.71 | | 21.18 |
| 1 year | 9.99 | | 21.18 |
| 3 years | 3.72 | | 21.18 |
| 5 years | 1.24 | | 21.18 |
| 10 years | 1.24 | | 24.48 |
| Manager | Title | Age | Since |
|---|---|---|---|
Chirag K. Patel
CEO | Chief Executive Officer | 59 | 2019-07-31 |
Chintu Patel
CEO | Chief Executive Officer | 54 | 2019-07-31 |
| Director of Finance/CFO | 58 | 2023-11-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Autor
BRD | Director/Board Member | 59 | 2023-11-06 |
J. Buchi
BRD | Director/Board Member | 71 | 2023-11-06 |
Jeffrey George
BRD | Director/Board Member | 52 | 2023-11-06 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/17/26 | Don | Director | -20,445 | 0.0064% | ||
| 9/11/26 | Exercice | Director | 40,890 | 0.0128% | ||
| 9/1/26 | Don | Executive/Senior Manager | -80,000 | 0.0251% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.49% | +6.26% | +93.18% | +409.50% | 7.1B | |
| -2.54% | +1.31% | +54.27% | +114.96% | 1,135B | |
| -1.42% | +3.23% | +38.56% | +74.44% | 636B | |
| +0.16% | +0.08% | +25.29% | +95.23% | 505B | |
| -0.31% | +3.09% | +44.14% | +64.80% | 378B | |
| -1.34% | -0.47% | +66.04% | +41.00% | 358B | |
| -0.68% | +2.65% | +22.98% | +50.39% | 295B | |
| -1.20% | +3.04% | +2.33% | +22.86% | 266B | |
| -1.79% | +1.57% | +50.56% | +59.08% | 237B | |
| -0.73% | -0.10% | +29.02% | +99.67% | 193B | |
| Average | -1.03% | +2.58% | +42.64% | +103.19% | 401.14B | |
| Weighted average by Cap. | -1.34% | +2.67% | +41.12% | +80.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.16B 2.82B 2.6B 2.36B 4.41B 300B 4.49B 31.33B 12.41B 157B 11.85B 11.59B 495B | 3.45B 3.08B 2.85B 2.58B 4.83B 328B 4.91B 34.26B 13.56B 172B 12.95B 12.68B 541B |
| Net income | 165M 148M 136M 124M 231M 15.68B 235M 1.64B 649M 8.22B 620M 607M 25.91B | 227M 202M 187M 169M 317M 21.51B 322M 2.25B 891M 11.27B 851M 832M 35.54B |
| Net Debt | 2.43B 2.17B 2.01B 1.82B 3.4B 231B 3.46B 24.16B 9.56B 121B 9.13B 8.94B 382B | 2.13B 1.9B 1.76B 1.59B 2.98B 202B 3.03B 21.16B 8.38B 106B 8B 7.83B 334B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-23 | US$20.38 | -0.49% | 4,925,129 |
| 26-10-22 | US$20.48 | +1.39% | 6,036,678 |
| 26-10-21 | US$20.20 | +1.81% | 4,660,217 |
| 26-10-20 | US$19.84 | +2.48% | 6,819,433 |
| 26-10-19 | US$19.36 | +0.94% | 2,098,715 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMRX Stock
Select your edition
All financial news and data tailored to specific country editions
